SWK Holdings Corporation is a specialized finance company. The Company operates through two segments: Finance Receivables and Pharmaceutical Development. The Finance Receivables segment is a healthcare capital provider, which offers sophisticated, customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Company’s Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical-stage biopharmaceutical company offering formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. This segment utilizes the technology platform to create a portfolio of royalty income.